Filing Flows › Lyell Immunopharma (LYEL) › Who owns the stock
Who owns Lyell Immunopharma (LYEL) stock
89 funds reported Lyell Immunopharma (LYEL) shares in their latest 13F filings, worth $238M in all. The largest holder is Arch Venture Management, LLC ($45.5M). Last quarter 44 funds added to their stakes and 28 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Arch Venture Management, LLC | 3,247,162 | $45.5M | unchanged | 2026-06-30 |
| MWG Caph | 1,008,116 | $31.0M | base | 2025-12-31 |
| Vanguard Group | 826,430 | $25.4M | increase | 2025-12-31 |
| GSK | 1,512,659 | $21.3M | unchanged | 2026-06-30 |
| MWG Management | 1,008,116 | $16.4M | new | 2025-09-30 |
| Vanguard Capital Management LLC | 786,774 | $11.1M | increase | 2026-06-30 |
| Orland Properties | 754,698 | $10.6M | unchanged | 2026-06-30 |
| BlackRock | 724,342 | $10.2M | increase | 2026-06-30 |
| Almitas Capital LLC | 581,407 | $8.2M | increase | 2026-06-30 |
| Foresite Capital Management V, LLC | 476,386 | $6.7M | decrease | 2026-06-30 |
| Millennium Management LLC | 367,473 | $5.2M | decrease | 2026-06-30 |
| Opaleye Management | 344,025 | $4.8M | increase | 2026-06-30 |
| venBio Partners LLC | 337,697 | $4.7M | new | 2026-06-30 |
| Geode Capital Management, LLC | 310,636 | $4.4M | increase | 2026-06-30 |
| Alphabet | 293,256 | $4.1M | unchanged | 2026-06-30 |
Lyell Immunopharma's latest quarter
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most LYEL stock?
By the latest 13F filings: Arch Venture Management, LLC ($45.5M); MWG Caph ($31.0M); Vanguard Group ($25.4M); GSK ($21.3M); MWG Management ($16.4M).
What is the short interest in LYEL?
1,398,232 shares were sold short at the 2026-10-15 settlement, 10.67% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.